Skip to main content
Berry Genomics Co.,Ltd logo

Berry Genomics Co.,Ltd — Investor Relations & Filings

Ticker · 000710 ISIN · CNE000000PN7 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,009 across all filing types
Latest filing 2016-12-04 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000710

About Berry Genomics Co.,Ltd

https://www.berrygenomics.com

Berry Genomics Co.,Ltd. is a biotechnology enterprise specializing in clinical genomics and genetic testing services. The company focuses on the research, development, and commercialization of genomic technologies for clinical applications. Its core portfolio includes non-invasive prenatal testing (NIPT), utilizing high-throughput sequencing to screen for chromosomal abnormalities. Beyond reproductive health, the company provides genomic solutions for oncology diagnostics, including early cancer screening and companion diagnostics, as well as testing for hereditary diseases. Berry Genomics leverages advanced sequencing platforms and proprietary bioinformatics pipelines to deliver precision medicine tools to healthcare providers and research institutions. The company is recognized for its role in the clinical application of Next-Generation Sequencing (NGS) and its extensive genomic databases used to enhance diagnostic accuracy and therapeutic outcomes.

Recent filings

Filing Released Lang Actions
关于所提供信息真实性、准确性和完整性的声明与承诺函
Regulatory Filings Classification · 95% confidence The document is a declaration and commitment letter regarding the truthfulness, accuracy, and completeness of information provided in relation to a major asset restructuring involving share issuance and acquisition of 100% equity of another company. It contains legal commitments and assurances from a transaction party about the information provided for the transaction. There are no financial statements, audit results, or detailed financial data. The document is a legal or regulatory statement related to a transaction but does not fit into categories like M&A filings (which require merger communications or proxy statements), nor is it a full audit or financial report. It is primarily a legal commitment letter related to a transaction. Given the nature and content, it best fits under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory or compliance documents that do not fit other categories.
2016-12-04 Chinese
关于所提供信息真实、准确和完整的声明与承诺函
Regulatory Filings Classification · 95% confidence The document is a formal declaration and commitment letter from Beijing Berry Genomics Co., Ltd. regarding the authenticity, accuracy, and completeness of information provided in relation to a major asset restructuring involving a share purchase. It contains no financial data, no report content, and no regulatory filing details beyond the commitment statement. The document is short (802 characters) and serves as a legal attestation rather than a financial report or announcement. It does not fit categories like Annual Report, Interim Report, or Capital Update. It is primarily a certification or attestation letter related to a transaction. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2016-12-04 Chinese
详式权益变动报告书
Major Shareholding Notification Classification · 95% confidence The document is titled "详式权益变动报告书" which translates to "Detailed Equity Change Report". It is issued by 成都天兴仪表股份有限公司 and involves detailed disclosures about changes in shareholding, including the increase in shareholding and shareholding ratio by specific individuals (高扬 and 侯颖). The document references relevant Chinese securities laws and regulations, and includes detailed sections on the purpose, method, funding source, impact analysis, and related agreements of the equity change. It also discusses share issuance, lock-up periods, and performance compensation agreements related to the equity change. The document is lengthy (15,000 characters) and contains substantive content about shareholding changes rather than just an announcement or summary. This matches the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. It is not an announcement of a report, nor a full annual or interim report, nor a proxy or voting result document. Therefore, the appropriate classification is MRQ with high confidence.
2016-12-04 Chinese
第七届监事会第五次临时会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions from the Supervisory Board meeting of Chengdu Tianxing Instrument Co., Ltd. It discusses approval of a major transaction involving issuance of shares to purchase assets and a significant asset sale, including detailed terms, pricing, lock-up periods, and compliance with relevant laws and regulations. It references multiple legal and regulatory frameworks such as the Company Law, Securities Law, and specific rules on major asset restructuring. The document includes voting results and mentions that the proposals require shareholder meeting approval. It also discusses audit and evaluation reports related to the transaction but does not itself contain full financial statements or comprehensive financial performance data. The document is a formal announcement of a capital/financing update and major asset transaction, not a full annual or interim report, nor a proxy or voting result announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2016-12-04 Chinese
中信建投证券股份有限公司关于公司本次重大资产重组前发生“业绩变脸”或重组存在拟置出资产情形相关事项之专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed independent financial advisor's special investigation opinion related to a major asset restructuring of Chengdu Tianxing Instrument Co., Ltd. It references regulatory requirements from the China Securities Regulatory Commission (CSRC) dated June 24, 2016, concerning performance changes before major asset restructuring and potential asset disposal. The document includes extensive analysis of compliance with commitments, operational norms, financial audit reports from 2013 to 2015, and asset valuation related to the restructuring. It is not a full annual or interim report but a specialized advisory opinion focused on the asset restructuring and related compliance and valuation matters. This fits the category of Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests, excluding full annual reports. The document length (over 14,000 characters) and detailed content confirm it is the report itself, not merely an announcement. Therefore, the appropriate classification is AR with high confidence. H1 2016
2016-12-04 Chinese
北京贝瑞和康生物技术股份有限公司2016年1-6月、2015年度、2014年度、2013年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report'. It contains detailed financial statements including consolidated and parent company balance sheets, income statements, cash flow statements, and notes to the financial statements for multiple years (2013 to mid-2016). The text includes the auditor's responsibilities, management's responsibilities, and the auditor's opinion, which are typical components of an audit report. The presence of detailed financial data and the auditor's opinion confirms this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters), indicating it is the full report, not just an announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR).
2016-12-04 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.